In a 100-patient study of Mia there were no reports of capsular contracture or rupture. The new Zensor™ RFID platform...
NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing...
~ A showcase of PF614 and PF614-MPAR ~SAN DIEGO, CA / ACCESSWIRE / October 13, 2023 / Ensysce Biosciences, Inc....
Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of...
SHELTON, CT / ACCESSWIRE / October 12, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), announces that the Company's President,...
STOCKHOLM, SWEDEN / ACCESSWIRE / October 12, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
STOCKHOLM, SE / ACCESSWIRE / October 12, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, October 12, 2023 -- Promore Pharma AB...
Ad hoc announcement pursuant to Article 53 of the SIX listing rulesDirect MagnetOs sales grew to CHF 20.4 million in...
KELOWNA, BC / ACCESSWIRE / October 11, 2023 / Tryp Therapeutics Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology...
NORFOLK, VA / ACCESSWIRE / October 11, 2023 / Insight Therapeutics, LLC, a contract research organization focused on improving the...
A global licensing agreement has been signed for the development and commercialization of SOFIE’s two investigational Gallium-68 and Fluorine-18 Fibroblast...
Company on track to achieve value-driving milestones before year-endHOUSTON, TX / ACCESSWIRE / October 11, 2023 / CNS Pharmaceuticals, Inc....
ANN ARBOR, MI / ACCESSWIRE / October 11, 2023 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary...
Collaboration underscores Conduit’s mission to advance promising treatments by developing assets that have already completed Phase I trialsSAN DIEGO and...
BERKELEY HEIGHTS, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
MC2-32 (RGRN-305) a first in class, oral therapy targeting multiple pathways involved in Hidradenitis Suppurativa (HS) achieves highly positive data...
Imdusiran data will be highlighted in late breaking presentation WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new...
First study of patients with metastatic prostate cancer to evaluate standard-of-care chemotherapy (docetaxel) combined with an antibody drug conjugate (PDS0301).Decrease...